Kornimate/medical-research-clean huggingface dataset:
dapsone 100 mg versus 50 as primary prophylaxis for pneumocystis carinii pneumonia (pcp) in patients with aids-related complex (arc)

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to determine which of 2 doses of dapsone is effective prophylaxis for pneumocystis carinii pneumonia (pcp) in patients with oral thrush or hairy leukoplakia and less than 400 cd4 lymphocytes per mm3. to determine whether the long-term toxicities associated with daily dapsone in this population are tolerable.


Eligibility criteria:
inclusion criteria the patient must have hiv positive antibody test and presence of oral thrush or hairy leukoplakia. * patient must be willing and able to sign informed consent. exclusion criteria co-existing condition: patients with the following are excluded: * prior pneumocystis carinii pneumonia (pcp) or aids-defining condition. * prophylaxis for pcp in preceding 3 months. * absence of detectable glucose-6-phosphate dehydrogenase (g6pd) activity. * prior type i hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone. * history of poor compliance. concurrent medication: excluded: * zidovudine (azt). patients with the following are excluded: * prior pneumocystis carinii pneumonia (pcp) or aids-defining condition. * prophylaxis for pcp in preceding 3 months. * absence of detectable glucose-6-phosphate dehydrogenase (g6pd) activity. * concurrent or prior therapy with zidovudine (azt). * prior type i hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone. * history of poor compliance. prior medication: excluded: * zidovudine (azt).

Keywords: aids-related opportunistic infections pneumonia, pneumocystis carinii leukoplakia, oral dapsone aids-related complex candidiasis, oral
exercise-induced ischemia and the influence of pain modulation in a nerve growth factor (ngf) model

Conditions: Pain Response; Hyperalgesia; Healthy Subjects

Summary: the purpose of this study is to investigate responses of pain and the maintenance of mechanical muscle hypersensitivity following an acute exercise-induced ischemic condition repeated over time in a prolonged ngf-sensitized muscle. additionally, the influence of the pain modulating system on prolonged ngf muscle hypersensitivity caused by peripheral mechanisms and central mechanisms will also be investigated.

the hypothesis is that an ischemic conditioning in a ngf-sensitized muscle is able to facilitate pain responses and that over time the pain modulation system is responsible for a subsequent reduction in muscle sensitivity towards mechanical pressure and a decrease in pain intensity following a period of ngf-induced muscle hypersensitivity.

Eligibility criteria:
inclusion criteria: * healthy and pain free volunteers exclusion criteria: * pregnancy * drug addiction defined as the use of cannabis, opioids or other drugs * previous neurologic, mental illnesses, or psychiatric diseases. * past history of chronic pain in the musculoskeletal system (muscle, joint, cartilage, connective tissue) * participation in other pain trials throughout the study period * lack of ability to cooperate * taking any analgesic 24 hours before the injections * performing any strenuous leg exercise through out the study period causing sore muscles

Keywords: ngf-induced hyperalgesia exercise-induced ischemic pain pain modulation ngf pain model
dietary pork, appetite and weight loss in human

Conditions: Appetite; Weight Loss

Summary: the entire study protocol will last 13 weeks. women will be randomly assigned to one of two experimental groups: high and low protein. all women will consume their unrestricted habitual diet during week 1 while baseline testing and measurements are taken. starting at week 2, women in both groups will be counseled to consume a 750 kcal/day energy deficit diet containing either the rda (lp group) or more than the recommended dietary allowance (rda) (hp group) for protein. the energy restriction period will continue for 12 weeks (through study week 13) and is expected to result in body weight reduction of approximately 17 pounds. testing and measurements will be repeated during week 13.


Eligibility criteria:
inclusion criteria: * eligible women will have a body mass index (bmi: weight (kg)/height (m2)) ranging from 26-36. * must be at least 21 years old. exclusion criteria: * women with medical conditions that might place them at risk for participating in the study or interfere with the successful completion of the study protocol will be excluded. * bmi \ 36. * younger than 21 years old.
antioxidant and immunomodulator properties of viusid in patients with chronic hepatitis c

Conditions: Chronic Hepatitis C

Summary: the pathogenesis of chronic hepatitis c (chc) is associated to severe oxidative stress and non-selective immunological disturbance that leads to necro-inflammation and progression of fibrosis. previous trials suggested that antioxidant and inmunostimulant therapies may have a beneficial effect. the purpose of the study is to evaluate whether viusid, a nutritional supplement with hepatoprotective properties, could ameliorate the oxidative stress and modulate the immune response in patients with chc and non-responders to pegylated interferon plus ribavirin, during 24 weeks of treatment.


Eligibility criteria:
inclusion criteria: * hcv infection confirmed on a positive test for anti-hcv antibody and hcv rna detectable in serum by polymerase chain reaction. * histological diagnosis of chronic hepatitis. * patients who were non-responders to previous treatment with pegylated interferon and ribavirin or who had contraindicated the antiviral treatment. * age between 18 and 65 years. * ability to provide informed consent. * absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g) exclusion criteria: * presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced liver disease, nonalcoholic steatohepatitis, metabolic and hereditary liver disease and α-1 antitrypsin deficiency). * pregnancy or lactation. * decompensated cirrhosis. * absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml. * refusal to participate in the study. * concomitant disease with reduced life expectancy. * severe psychiatric conditions. * drug dependence. * co-infection with hepatitis a or b or hiv. * pregnancy.

Keywords: chronic hepatitis c oxidative stress antioxidant cytokines nutritional supplement
treatment of premature ovarian insufficiency using bone marrow cells

Conditions: Premature Ovarian Insufficiency

Summary: investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-mullerian hormone. autologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.

premature ovarian insufficiency is a clinical syndrome characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotrophin hormones and low estrogen and anti-mullerian hormone. the average age for menopause is 50-52 years in the developed world ,it is believed that about 1% for women less than 40 years of age and 0.1 in less than 30 years of age has premature ovarian insufficiency. etiology of poi may be genetic, chromosomal, or auto immune.in addition to cancer treatment and surgical causes. hormonal replacement therapy is recommended for poi patients to alleviate vasomotor symptoms in addition to prevent osteoporosis and ischemic heart disease. regenerative medicine is a new medical approach to treat variety of diseases involving many tissues or organs in human body using cells, biological products instead of drugs or physical factors. autologous use of stem cells from bone marrow or adipose tissue (stromal vascular fraction) or platelet rich plasma are alternative safe minimal manipulative products that can provide a solution to this clinical syndrome. only few cases had been mentioned in the literature offering autologous stem cells for treating poi including bone marrow or adipose derived stem cells in addition to mesenchymal stem cells expanded invitro. the investigator use autologous bone marrow concentrate with transvaginal approach under ultrasound guidance to treat poi.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of premature ovarian insufficiency. 2. ineffective hormonal therapy. 3. biochemical evidence of high gonadotropins. exclusion criteria: 1. solid or hematological malignancies. 2. bleeding disorders. 3. rejection of the procedure.

Keywords: premature ovarian failure,bone marrow,treatment
oxidative stress in standard laparoscopic vs single port cholecystectomy

Conditions: Uncomplicated Cholelithiasis; Cholecystectomy; Laparoscopy; Standard Technique; Single Port Laparoscopy

Summary: study of oxidative stress markers in order to assess whether there are differences between standard laparoscopic cholecystectomy vs single port cholecystectomy for uncomplicated cholelithiasis


Eligibility criteria:
inclusion criteria:uncomplicated cholelithiasis american society of anesthesiologists (asa) i or ii no previous operations in upper abdomen body mass index (bmi) - exclusion criteria:cholecystitis asa \> ii bmi\>30 previous operations in upper abdomen previous operations in intestine smokers alcohol drugs -

Keywords: sils oxidative stress 8-epipgf2a sils vs standard laparoscopic cholecystectomy
post bariatric surgery acute kidney injury: incidence and risk factors

Conditions: Bariatric Surgery; Acute Kidney Injury

Summary: bariatric surgery is the most effective means of inducing and maintaining sustained weight loss. apart from the weight loss effect, bariatric surgery leads to the remission of chronic metabolic disorders such as type 2 diabetes (t2d) and hypertension . recent studies have shown that bariatric surgery improves renal perfusion and glomerular function and reduces inflammatory markers which can lead to an improvement of microalbuminuria and proteinuria however, acute kidney injury (aki) can complicate the postoperative course after bariatric surgery. the etiology of aki after bariatric surgery can be multifactorial and complex in obese population . the preexisting factors such as diabetes, hypertension, and ckd in these patients can additionally worsen the renal insult during the postoperative period . postoperative aki is associated with increase morbidity and mortality especially in cases of severe aki that requires dialysis support . identifying the high-risk patients for development of postoperative aki would prevent renal injury. our aim was to study the incidence and etiology of postoperative aki after bariatric surgery . causes of post bariatric surgery aki include . pre renal causes :dehydration ( repeated vomiting and diarrhoea)which are common complications post bariatric surgery , haemorrhagic shock (from the site of anastomosis , ulcer ) , septic shock ( leakage , pneumonia) , hypotension and respiratory depression secondary to narcotic overdose. rena causes: contract induced nephropathy after using ct scan guided drainage of intra abdominal collection post operative, rhabdomylosis , drug induced nephropathy e.g :using of iv vancomycin for sepsis in icu .. many causes can lead to aki post bariatric surgery but the common two causes are dehydration and sepsis .


Eligibility criteria:
1. inclusion criteria: 1. age more than 18 years old undergo bariatric surgery . 2. bmi ≥30 : ( bmi = weight in kg / height in m²) 2. exclusion criteria: 1. previous kidney diseases(aki , ckd) . 2. patients unfit for surgery e.g ( comorbidities : chd , lcf ) 3. drugs : (ace-i , arbs, and nsaids)

Keywords: bariatric surgery acute kidney injury
reborn lifestyle adjustment program

Conditions: Breast Cancer; Quality of Life

Summary: the aim of this study is to investigate the effects of the reborn lifestyle regulation program on physical activity, fatigue level, pain, mental health burden and quality of life in breast cancer patients.


Eligibility criteria:
inclusion criteria: * being a female individual aged 18 or older * have been diagnosed with stage i, ii, or iii breast cancer * at least 6 months have passed since the completion of chemotherapy * approval by an oncologist to participate in the study * having internet access and the ability to connect online * scoring above 23 on a standardized mini mental status examination test * being in the contemplation stage according to the transtheoretical model exclusion criteria: * having a neurological or systemic disease that could significantly affect the course of the intervention * having metastasis that could impact the sustainability of the study * suffering from neuropathic pain * having participated in a healthy lifestyle program within the last 3 months
a study to evaluate the effect of asp0456 in patients with constipation predominant irritable bowel syndrome

Conditions: Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Summary: this study is to investigate the efficacy, safety, and plasma concentration change of asp0456 in patients with constipation-predominant irritable bowel syndrome.

this study is a multicenter, double-blind, placebo-controlled, parallel-group, comparative study to investigate dose-responses of efficacy, safety, and pharmacokinetics of asp0456 in patients with constipation-predominant irritable bowel syndrome (ibs-c) according to the rome iii diagnostic criteria (2006 revised edition, established by the rome iii committee) after oral administration of asp0456.

Eligibility criteria:
inclusion criteria: * patients who had abdominal pain or discomfort repeatedly for at least 3 days per month during the 3 months before screening examination associated with at least 2 out of the following 3 conditions: (1) improvement with defecation; (2) onset associated with a change in frequency of stool; and (3) onset associated with a change in form (appearance) of stool, and had the above symptom (ibs symptom) 6 months or more before the screening examination period. * patients with ≥25% of stools hard or lumpy (with each bowel movement occurring without antidiarrheal, laxative, suppository or enema) and \<25% of them loose (mushy) or watery during the 3 months before the screening examination. * patients who had pancolonoscopy or contrast enema (or sigmoidoscopy) after the onset of ibs symptom and had no organic changes. exclusion criteria: * patients with a history of surgical resection of the stomach, gallbladder, small intestine or large intestine * patients with other concurrent diseases that may affect the digestive tract passage or large intestinal function * patients with other concurrent diseases that may affect the assessment of abdominal pain/discomfort * patients with blood pressure, pulse rate, clinical laboratory test, or 12-lead ecg at the time of screening examination that was rated as grade 2 or greater on the "severity criteria for drug adverse reaction" and judged to be clinically significant

Keywords: irritable bowel syndrome (ibs) linaclotide constipation asp0456
safety and efficacy study of bimatoprost in patients with glaucoma or ocular hypertension

Conditions: Ocular Hypertension

Summary: the purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * clinical diagnosis of glaucoma or ocular hypertension in both eyes * patient requires iop-lowering drug in both eyes exclusion criteria: * uncontrolled medical conditions * ocular seasonal allergies within the past 2 years
neurodevelopment after early iron supplementation

Conditions: Iron Deficiency; Anemia of Prematurity; Neurodevelopmental Delay

Summary: background: iron deficiency in early childhood may impair neurodevelopment. aim: to examine whether early iron supplementation improved neurodevelopment in preterm infants. method: children who participated in a clinical trial of iron supplementation were invited for a neurodevelopmental follow-up examination at the time of school entry.

children with a birth weight of \< 1301g who participated in a randomized controlled trial of early versus late enteral iron supplementation were evaluated applying a standardized neurological evaluation, the kaufmann assessment battery for children, and the gross motor function classification scale (gmfcs) at the age of school entry. severe disability was defined as any of the following: any abnormal neurological examination associated with a severely impaired mobility (gmfcs\>1), severe cognitive impairment (mental processing composite (mpc) \ 85) and the absence of any severe hearing and visual impairment.

Eligibility criteria:
inclusion criteria: * inborn infants with a birth weight of \<1301g admitted between june 1996 and june 1999 exclusion criteria: * major anomalies, hemolytic disease, twin-to-twin transfusion syndrome, missing parental consent

Keywords: neurocognitive outcome preterm infant very low birth weight iron deficiency iron supplementation
efficacy and safety of d005 vaginal mousse on bacterial vaginosis

Conditions: Bacterial Vaginosis &#X7C; Vaginal &#X7C; Microbiology

Summary: this is a randomised, double-blind clinical investigation to evaluate the efficacy and safety of d005 vaginal mousse compared to placebo, in women with bacterial vaginosis. the study will be conducted at one site in scotland, united kingdom and at six different sites in sweden. the study population will consist of approximately 83 female subjects.


Eligibility criteria:
inclusion criteria: 1. willingness and ability to provide informed consent 2. female in fertile age 3. age ≥18 years 4. bacterial vaginosis, as defined by the following criteria (amsel criteria): 1. a fishy odour (i.e., a positive whiff test) of the vaginal discharge with the addition of a drop of potassium hydroxide (koh) 2. presence of clue cells (≥20%) 3. off-white (milky or gray), thin, homogeneous discharge 5. refrain from using any intravaginal products during the investigation period 6. refrain from sexual intercourse during treatment. refrain from sexual intercourse or use a condom during rest of the investigation period to visit 3. exclusion criteria: 1. hypersensitivity or allergy to the investigational devices or to chemically related products 2. current use of an intrauterine device. 3. current pregnancy or intention to become pregnant within 1 month after treatment 4. antibiotic treatment within 2 weeks before treatment 5. signs of other infections (such as chlamydia, gonorrhoea, trichomonas, candida, hsv or hpv) requiring specific antibiotic, antifungal or other treatment at screening. 6. immunosuppression therapy (allergy medications allowed) at the discretion of the pi 7. existing or suspected vaginal or cervical cancer or ulcer 8. unprotected vaginal sex within 24 hours prior to visit 1 9. be identified by the investigator as inappropriate from a medical or compliance perspective to participate in this investigation (e.g. hysterectomised or inability to report daily using smartphone/computer \[ediary\]).

Keywords: women's health bakteriell vaginos
asenapine in the treatment of older adults with bipolar disorder

Conditions: Bipolar Disorder

Summary: objectives: the investigators propose a first-ever, prospective trial of asenapine in older adults with bipolar disorder (bd) to evaluate effects on mood symptoms, tolerability and functional/general health status. given the dearth of treatment data on older adults with bd, findings are likely to be of substantial clinical interest, may inform larger future studies and will assist in refining bipolar treatment recommendations. hypotheses: primary: asenapine therapy will be associated with reduced bipolar manic and depressive symptoms in older adults with bd. secondary: asenapine therapy will be associated with improved functional and general health status, improved global psychopathology, and good tolerability in older adults with bd.


Eligibility criteria:
inclusion criteria: * subjects must have type i bipolar disorder by dsm-iv criteria confirmed on the mini neuropsychiatric interview (mini) * subjects must be age 60 or older * subjects must have sub-optimal response to current psychotropic management including at least one of the following: 1. behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence 2. diminished ability to take care of basic personal needs in their place of residence due to symptoms of bd exclusion criteria: * history of intolerance or resistance to asenapine * clinical diagnosis of dementia or mini-mental state (mmse) \< 24 * history of tia, stroke or mi within the past 12 months * medical illness that is the clear, underlying etiology of bd * unstable medical illness or condition including prolonged qt interval, which in the opinion of the study investigators, is likely to affect the outcome of the study or the subject's safety * dsm-iv substance dependence (except nicotine or caffeine) within the past 3 months. * rapid cycling bd defined as 4 or more discrete mood episodes within the previous 12 months. * at high risk for self-harm or suicide
anti-tumour effects & tolerability of faslodex alone or in combination with arimidex in post menopausal women prior to surgery for primary breast cancer

Conditions: Breast Cancer

Summary: to compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of faslodex and arimidex with faslodex alone and arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.


Eligibility criteria:
inclusion criteria: * postmenopausal women. * biopsy confirmation of primary breast cancer. * oestrogen receptor positive tumour. * fit for surgery within one month. * written informed consent to participate in the study exclusion criteria: * previous treatment with any anti-hormonal therapy for breast cancer. * previous radiotherapy to the primary tumour. * previous chemotherapy for the primary tumour.